23andMe has found a buy­er. Re­gen­eron will buy the strug­gling 23andMe through its court-su­per­vised sale for $256 mil­lion, the com­pa­nies dis­closed Mon­day morn­ing. The move comes af­ter a roller coast­er for 23andMe in the past few years, as the ge­net­ics test­ing com­pa­ny ex­pe­ri­enced a da­ta breach, saw its stock price crater, end­ed its ther­a­peu­tics dis­cov­ery work, saw its en­tire board de­part, slashed its clin­i­cal tri­als, re­ject­ed mul­ti­ple take­out bids from its CEO, and then filed for bank­rupt­cy...